Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2003
11/06/2003WO2003091213A1 Novel amide derivatives or salts thereof
11/06/2003WO2003091211A1 Novel heteroaryl compounds
11/06/2003WO2003091207A2 Method of preparing amine stereoisomers
11/06/2003WO2003090912A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
11/06/2003WO2003090869A1 Lxr modulators
11/06/2003WO2003090784A1 Treatment of metabolic syndrome
11/06/2003WO2003090783A1 Preventive/remedy for diabetes
11/06/2003WO2003090777A1 Combination therapy to treat a catabolic state in a patient
11/06/2003WO2003090768A1 Herbal product to be administered to diabetic individuals and the production method thereof
11/06/2003WO2003090766A1 Arsenic therapy for apls-type autoimmune lymph-oproliferative syndrome in mice and humans
11/06/2003WO2003090764A1 Mineral absorption promoter
11/06/2003WO2003090759A1 Difructose anhydride-containing composition and use thereof
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090749A1 Use of berberine with high solubility in preparation of medicament
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090742A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan
11/06/2003WO2003090726A2 Chewable soft capsule
11/06/2003WO2003090725A1 Capsule preparation
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090640A2 Microbial cellulose wound dressing for treating chronic wounds
11/06/2003WO2003090557A1 Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
11/06/2003WO2003090547A1 A composition comprising waxy acids for effecting serum cholesterol levels
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055983A3 Targeted retrograde gene delivery to motor neurons
11/06/2003WO2003055880A3 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
11/06/2003WO2003052124A3 Screening method for agents useful in treating diabetes
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003026561A3 Flavonoids for treatment of diabetes
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin
11/06/2003WO2002102298A3 Process for the preparation of dispersions
11/06/2003WO2002096445A3 Food compositions for reducing insulin resistance
11/06/2003WO2002094799A3 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/06/2003WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002066649A8 ANTI-INTERFERON-α ANTIBODIES
11/06/2003WO2002059117A8 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
11/06/2003WO2002059108A8 Melanocortin receptor agonists
11/06/2003WO2002059107A8 Substituted piperidines/piperazines as melanocortin receptor agonists
11/06/2003WO2002053742A3 Proteins and nucleic acids encoding same
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002040039A3 In vivo use of water absorbent polymers
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002026737A8 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002009639A3 Methods and pharmaceutical compositions for healing wounds
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003WO2000033865A8 Methods of inhibiting ectopic calcification
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208059 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208045 Binds to Osteoclastogenesis Inhibitory Factor (OCIF) binding molecule (OBM)
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207930 Valsartan salts
11/06/2003US20030207924 Compounds that modulate PPAR activity and methods of preparation
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207916 Thiazole or oxazole derivatives such as (4-(4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl)-5-oxo -5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid
11/06/2003US20030207915 Compounds that modulate PPAR activity and methods of preparation
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207898 Sulfides such as N-(2-(((6- chloro-1,3-benzodioxol-5-yl)methyl )thio)phenyl)thiophene-2-carboxamide used for controlling metabolism of lipids and prophylaxis of diabetes, Alzheimers disease, atherosclerosis, dyslipidemia and genetic disorders
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207864 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular
11/06/2003US20030207860 Neuropeptide Y Y5 receptor antagonists
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207823 Novel diabetes imaging probes
11/06/2003US20030207814 Novel guanidinyl derivatives
11/06/2003US20030207810 Method of treating malignancy associated hypercalcemia using active vitamin D analogues
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207317 Novel nucleic acid isolated from Tetrahymena which codes for a triterpenoid cyclase, its production, and use
11/06/2003US20030207301 Assay for the detection of factors that modulate the expression of INGAP
11/06/2003US20030207251 For drug screening
11/06/2003US20030206977 Natural tea for curing men's impotence and a method for manufacturing the same
11/06/2003US20030206975 Compositions and methods of use for extracts of magnoliaceae plants
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003DE20313224U1 Synergistic composition for treating metabolic syndrome, comprises swellable or gel-forming anorectic agent for inducing satiation and polymeric or other hypocholesterolemic and/or antidiabetic agent
11/06/2003CA2484306A1 Prophylactic and therapeutic agent of diabetes mellitus
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483701A1 Constitutively active histamine h3 receptor mutants and uses thereof
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483263A1 Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
1 ... 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 ... 1298